Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 5/20 | 1.00 |
| ▸ | HTR7 | P34969 | 5/20 | 1.00 |
| ▸ | HTR1D | P28221 | 4/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | HTR3A | P46098 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.80 |
| ▸ | RAD52 | P43351 | 1/20 | 0.80 |
| ▸ | BLM | P54132 | 1/20 | 0.80 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.58 |
| ▸ | SPR | P35270 | 1/20 | 0.55 |
| ▸ | HTR2B | P41595 | 3/20 | 0.50 |
| ▸ | HTR1A | P08908 | 3/20 | 0.50 |
| ▸ | HTR2C | P28335 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29361176 | 1.00 | HTR6 (1.00) | HTR6HTR7HTR1DCYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL5791576 | 0.98 | HTR6 (0.97) | HTR6HTR7HTR1DCYP1A2CYP3A4 | |
| Fumaric Acid SCHEMBL1320838 | 0.89 | NPSR1 (1.00) | HTR6HTR7HTR1DCYP1A2CYP3A4 | |
| Maleic Acid SCHEMBL1320833 | 0.89 | NPSR1 (1.00) | HTR6HTR7HTR1DCYP1A2CYP3A4 | |
| Serotonin SCHEMBL27310578 | 0.88 | HTR1D (0.78) | HTR6HTR7HTR1DCYP1A2CYP3A4 | |
| SCHEMBL21374161 | 0.85 | HTR7 (0.74) | HTR6HTR7HTR1DCYP1A2CYP3A4 | |
| SCHEMBL7886752 | 0.83 | HTR1D (0.71) | HTR6HTR7HTR1DCYP1A2CYP3A4 | |
| SCHEMBL12352616 | 0.81 | HTR7 (0.68) | HTR6HTR7HTR1DCYP1A2CYP3A4 | |
| SCHEMBL26989650 | 0.81 | HTR6 (0.68) | HTR6HTR7HTR1DCYP1A2CYP3A4 | |
| SCHEMBL28750432 | 0.81 | HTR6 (0.68) | HTR6HTR7HTR1DCYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 720 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4358962-B1 | TREATMENT FOR AUTOIMMUNE DISEASES COMPRISING NALTREXONE OR A METABOLITE OR ANALOG THEREOF, A CANNABINOID AND A 5-HT RECEPTOR AGONIST | LDN PHARMA LTD (GB) | 2026-02-04 | — | — | EP | claimed |
| US-20250281481-A1 | NALTREXONE FOR BOOSTING THE THERAPEUTIC UTILTY OF 5-HT RECEPTOR AGONISTS | LDN Pharma Limited (GB) | 2025-09-11 | — | — | US | claimed |
| US-20240342312-A1 | A SHORTENED P63-PROTEIN DOMAIN TO ENHANCE HUMAN CARDIAC REPROGRAMMING | BAYLOR COLLEGE OF MEDICINE (US) | 2024-10-17 | — | — | US | claimed |
| US-20240293395-A1 | NALTREXONE FOR IMPROVING THE EFFECTIVENESS OF 5-HT RECEPTOR SUBTYPE 2A, 2B or 2C AGONISTS | LDN Pharma Limited (GB) | 2024-09-05 | — | — | US | claimed |
| US-20240285612-A1 | COMPOSITIONS COMPRISING AN AGONIST OF 5-HYDROXYTRYPTAMINE (5-HT) RECEPTOR SUBTYPE 3 | LDN Pharma Limited (GB) | 2024-08-29 | — | — | US | claimed |
| US-20240285613-A1 | TREATMENT FOR AUTOIMMUNE DISEASES | LDN Pharma Limited (GB) | 2024-08-29 | — | — | US | claimed |
| EP-3259346-B1 | P63 INACTIVATION FOR THE TREATMENT OF HEART FAILURE | BAYLOR COLLEGE MEDICINE (US) | 2024-08-07 | — | — | EP | claimed |
| US-20240252535-A1 | CELLULAR COMPOSITION FOR TREATMENT OF DISEASES, DISORDERS OR CONDITIONS AND METHOD OF USE | YZTHERAPEUTIC PERFORMANCE LTD. (IL) | 2024-08-01 | — | — | US | claimed |
| US-20240228941-A1 | ELECTROPORATION, DEVELOPMENTALLY-ACTIVATED CELLS, PLURIPOTENT-LIKE CELLS, CELL REPROGRAMMING AND REGENERATIVE MEDICINE | REID CHRISTOPHER B (US) | 2024-07-11 | — | — | US | claimed |
| EP-4380959-A1 | A SHORTENED P63-PROTEIN DOMAIN TO ENHANCE HUMAN CARDIAC REPROGRAMMING | Baylor College of Medicine (US) | 2024-06-12 | — | — | EP | claimed |
| US-20020161016-A1 | As-needed administration of tricyclic and other non-SRI antidepressant drugs to treat premature ejaculation | VIVUS LLC (F/K/A VIVUS, INC.) | 2002-10-31 | — | — | US | claimed |
| WO-2002041883-A2 | AS-NEEDED ADMINISTRATION OF TRICYCLIC AND OTHER NON-SRI ANTIDEPRESSANT DRUGS TO TREAT PREMATURE EJACULATION | VIVUS, INC. (US) | 2002-05-30 | — | — | WO | claimed |
| WO-2002038142-A2 | SEROTONERGIC COMPOSITIONS AND METHODS FOR TREATMENT OF MILD COGNITIVE IMPAIRMENT | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2002-05-16 | — | — | WO | claimed |
| US-20010008896-A1 | Administration of active agents, including 5-HT receptor agonists and antagonists, to treat premature ejaculation | SMITH WILLIAM L (US) | 2001-07-19 | — | — | US | claimed |
| EP-1083918-A1 | NOVEL THERAPEUTIC AGENTS THAT MODULATE 5-HT RECEPTORS | Advanced Medicine, Inc. (US) | 2001-03-21 | — | — | EP | claimed |
| EP-1082118-A2 | METHODS FOR THE NORMALIZATION OF SEXUAL RESPONSE AND AMELIORATION OF LONG TERM GENITAL TISSUE DEGRADATION | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2001-03-14 | — | — | EP | claimed |
| WO-1999064044-A1 | NOVEL THERAPEUTIC AGENTS THAT MODULATE 5-HT RECEPTORS | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | claimed |
| WO-1999062502-A2 | METHODS FOR THE NORMALIZATION OF SEXUAL RESPONSE AND AMELIORATION OF LONG TERM GENITAL TISSUE DEGRADATION | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 1999-12-09 | — | — | WO | claimed |
| US-5922341-A | Local administration of pharmacologically active agents to treat premature ejaculation | VIVUS, INCORPORATED (US) | 1999-07-13 | — | — | US | claimed |
| US-5521183-A | Use of 5-HT ligands as anti-pruritic agents | ALLERGAN (US) | 1996-05-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161016-A1 | As-needed administration of tricyclic and other non-SRI antidepressant drugs to treat premature ejaculation | HTR5A, HTR1A, MAOA | HTR6 10/4885HTR7 16/4885HTR1D 12/4885 |
| US-20240293395-A1 | NALTREXONE FOR IMPROVING THE EFFECTIVENESS OF 5-HT RECEPTOR SUBTYPE 2A, 2B or 2C AGONISTS | HTR2C, HTR2B, HTR2A | HTR6 16/4885HTR7 17/4885HTR1D 12/4885 |
| US-20250281481-A1 | NALTREXONE FOR BOOSTING THE THERAPEUTIC UTILTY OF 5-HT RECEPTOR AGONISTS | VDR, OPRD1, HTR1A | HTR6 33/4885HTR7 18/4885HTR1D 6/4885 |
| US-20240285612-A1 | COMPOSITIONS COMPRISING AN AGONIST OF 5-HYDROXYTRYPTAMINE (5-HT) RECEPTOR SUBTYPE 3 | HTR3A, HTR3C, HTR1A | HTR6 11/4885HTR7 19/4885HTR1D 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.